VivoSim Labs, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
VivoSim Labs, Inc. (VIVS) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $120.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-12
- VivoSim Labs, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $120.00K, a 7.14% increase year-over-year.
- VivoSim Labs, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $118.00K, a 6.31% increase year-over-year.
- VivoSim Labs, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $116.00K, a 6.42% increase year-over-year.
- VivoSim Labs, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $114.00K, a 6.54% increase year-over-year.
- VivoSim Labs, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2026 was $460.00K, a 6.48% increase from fiscal 2025.
- VivoSim Labs, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $432.00K, a 6.40% increase from fiscal 2024.
- VivoSim Labs, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $406.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $120.00K 10-Q · filed 2026-08-12 | $238.00K derived: sum of 2 quarters · filed 2026-08-12 | $354.00K derived: sum of 3 quarters · filed 2026-08-12 | $468.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $118.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-14 | $234.00K derived: sum of 2 quarters · filed 2026-07-14 | $348.00K derived: sum of 3 quarters · filed 2026-07-14 | $460.00K 10-K · filed 2026-07-14 |
| 2025-12-31 | $116.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-11 | $230.00K derived: sum of 2 quarters · filed 2026-02-11 | $342.00K 10-Q · filed 2026-02-11 | $453.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-09-30 | $114.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-06 | $226.00K 10-Q · filed 2025-11-06 | $337.00K derived: sum of 3 quarters · filed 2026-08-12 | $446.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $112.00K 10-Q · filed 2026-08-12 | $223.00K derived: sum of 2 quarters · filed 2026-08-12 | $332.00K derived: sum of 3 quarters · filed 2026-08-12 | $439.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $111.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-14 | $220.00K derived: sum of 2 quarters · filed 2026-07-14 | $327.00K derived: sum of 3 quarters · filed 2026-07-14 | $432.00K 10-K · filed 2026-07-14 |
| 2024-12-31 | $109.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-11 | $216.00K derived: sum of 2 quarters · filed 2026-02-11 | $321.00K 10-Q · filed 2026-02-11 | |
| 2024-09-30 | $107.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-06 | $212.00K 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | $105.00K 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | $406.00K 10-K · filed 2025-06-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |